An exploratory study of the association between SORL1 polymorphisms and sporadic Alzheimer’s disease in the Han Chinese population

Abstract

In previous studies, we reported that the sortilin-related receptor, L (DLR class) A repeats containing (SORL1) gene single nucleotide polymorphisms (SNPs) are associated with the risk of sporadic Alzheimer’s disease (SAD) in the Han Chinese population. To further explore the relationships between SORL1 genetic variants and SAD, we conducted a two-step study. Sequencing analysis in 50 case samples identified 14 SNPs within the promoter and untranslated region of the SORL1 gene. Subsequent genotyping analysis in 106 patients with SAD and 179 healthy controls detected a significant association between the “G” allele of SNP rs1133174 in the 3′ untranslated region of the SORL1 gene and SAD risk (odds ratio =1.92, 95% confidence interval [95% CI] =1.28–2.90, adjusted P=0.028). In addition, “G” allele carriers of rs1133174 (GA + GG) have a 2.15-fold increased risk of SAD compared to noncarriers (AA) (adjusted P=0.042). However, no significant positive associations were observed in the other 13 SNPs within the SORL1 gene. These preliminary findings suggest that the SORL1 SNP rs1133174 may be a potential risk locus for SAD in the Han Chinese population.

Keywords:

• SORL1
• Alzheimer’s disease
• polymorphism
• Han Chinese
• association

Introduction

Alzheimer’s disease (AD) is an age-related progressive neurodegenerative disorder characterized by impairments in memory and other cognitive functions.¹ Sporadic AD (SAD) affects the majority of patients with AD, and it is a most common polygenic multifactorial disease suggested to be the result of interactions of genetic and environmental factors.² Amyloid precursor protein (APP) and the presenilin genes 1 and 2 (PSEN1 and PSEN2) may be involved in early-onset familial AD, and currently, the ε4 allele of the apolipoprotein E gene (APOE ε4) is the only well-established susceptibility gene for late-onset AD.

The sortilin-related receptor, L (DLR class) A repeats containing (SORL1, also called LR11 or sorLA) gene, is a member of the low-density lipoprotein receptor family that reduces amyloid-β (Aβ) production by regulating the intracellular transport and processing of APP.^3–5 Moreover, as an APOE receptor, SORL1 is a likely biomarker for AD because of its interaction with APOE, A imaging study observed the effects of SORL1 variation on the brain microstructure during the neurodevelopmental phases of the human lifepan.⁶ Importantly, converging evidence from genetic and biological studies indicates that SORL1 could have an important role in AD susceptibility.^7–9 Notably, actual functional risk loci within the SORL1 gene still remain unknown. Previous studies suggest that several rare and functional variants might play a crucial role in the development of AD.^10,11 We reported that SORL1 genetic polymorphisms are significantly associated with susceptibility to SAD.^12,13 To further explore the functional genetic variants within the SORL1 gene associated with SAD risk, we designed the present two-step study. We first sequenced the promoter, and the 5′ and 3′ untranslated regions (UTRs) in a total of 50 patients with SAD. All 14 single nucleotide polymorphisms (SNPs) were then genotyped and analyzed in the Han Chinese population.

Materials and methods

Study population

A total of 50 patients with SAD, including 25 women and 25 men (75.6±9.8 years at recruitment), were assessed in the first step. In the genotyping step, the participants used in this case-control study included 106 unrelated patients (56 women and 50 men aged 76.4±10.5 years at recruitment), and 179 unrelated healthy control subjects (96 women and 83 men aged 78.2±8.7 years at recruitment). All participants were of Chinese Han descent and were recruited from the cities of Wuxi and Nanjing in Jiangsu province. A clinical diagnosis of probable AD was established according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association. Healthy subjects were recruited through advertisement. Cognitive function was assessed by two skilled professional psychiatrists using the Mini-Mental State Examination. The demographic characteristics of the study participants are listed in Table 1.

Table 1 Demographic characteristics of the study subjects

	Control, n (%)	SAD, n (%)
Total	179	106
Female	96 (53.6)	56 (52.8)
Male	83 (46.4)	50 (47.2)
Age, years	78.2±8.7	76.4±10.5
Age of onset	–	71.1±9.7
Occupation	Retired	Retired
MMSE	28.2±2.5	16.1±6.4*

Note: Values represent mean ± SD where noted,

* P<0.05, SAD vs controls.

Abbreviations: MMSE, Mini-Mental State Examination; SAD, sporadic Alzheimer’s disease; SD, standard deviation.

The clinical study was in compliance with the World Medical Association Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. The Ethics Committees of the Wuxi Health Mental Center approved this study. We excluded anyone who was not born in Jiangsu or whose family was not born in Jiangsu according to the self-reporting of their paternal grandparents and their place of birth. In addition, all patients and controls were not blood relations. Before enrollment in this study, all participants provided written consent forms.

DNA extraction

Blood samples were collected from all participants using the K₂ EDTA tubes, and a Blood Genotyping DNA Extraction Kit (Tiangen Biotech, Beijing, People’s Republic of China) was used to extract genomic DNA from 150 μL of peripheral blood. The DNA samples were then stored at −80°C for genotype analysis.

DNA sequencing

We performed sequencing of the SORL1 gene (chromosome 11, NC_000011.10, GRCh38) including 2,500 bp in the promoter and 5′ UTR and 4,195 bp in the 3′-UTR using the genomic DNA of 50 patients with SAD. The purified polymerase chain reaction products were sequenced using the ABI3730XL genetic analyzer according to the manufacturer’s instructions (Applied Biosystems, Foster City, CA, USA). The sequences were analyzed with Laser-Gene (DNASTAR, Inc., Madison, WI, USA) and Mutation Surveyor (Softgenetics, State College, PA, USA).

SNP genotyping

The genotypes of 14 SNPs were analyzed by Shanghai Biowing Applied Biotechnology Co., Ltd (www.biowing.com.cn) using the ligase detection reaction-polymerase chain reaction (LDR-PCR) method.^13–15 Genomic DNA extracted from the clinical samples was first subjected to multiplex PCR to obtain a PCR product that included SNPs. This PCR product and the LDR probes were then subjected to a multiplex LDR reaction with a DNA sequencer to detect the products. The genotype call rate is 100% and 95% for controls and patients, respectively.

Statistical analysis

Our statistical analyses were performed using the PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/) and SPSS 17.0 software (IBM Corporation, Armonk, NY, USA) and included association studies, Hardy–Weinberg equilibrium (HWE) tests, and the calculation of genotype and allele frequencies in SAD and healthy control subjects. Haplotype analysis was conducted using the SHEsis software (http://analysis.bio-x.cn/myAnalysis.php/).¹⁶ Linkage disequilibrium was analyzed using the Haploview software (http://www.broadinstitute.org/haploview/). Power calculations for our sample size were calculated using the PS software (http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize),^17,18 and functional prediction was performed using the rSNPBase (rsnp.psych.ac.cn/).¹⁹

Results

A total of 14 SNPs were detected in the sequencing analysis, which were previously reported in the SNP database established by the National Center for Biotechnology Information (Table 2). Our HWE tests indicated that the allelic frequency distribution of the 14 SORL1 polymorphisms in the 106 patients with SAD and 179 healthy controls do not deviate significantly from HWE (Table 3). The power of the present association study is approximately 65% for higher frequency variants using the PS software (assumption condition: α=0.05, P₀=0.2, n=106, m=1.7, Ψ=2.0).

Table 2 Identified SNPs by sequencing the SORL1 gene in 50 patients with SAD

SNP no	SNP in dbSNP	Allele‡	Position in NC_000011.10	SNP property
1	rs57785427	A/C	121449848	5′-UTR
2	rs4935774	C/T	121451045	5′-UTR
3	rs140041029	T/G	121451128	5′-UTR
4	rs189323512	C/T	121629830	3′-UTR
5	rs10892762	G/A	121630529	3′-UTR
6	rs117097913	G/A	121630583	3′-UTR
7	rs10790449	T/C	121630697	3′-UTR
8	rs1133174	G/A	121631046	3′-UTR
9	rs1131497	C/G	121632036	3′-UTR
10	rs3087925	A/G	121632059	3′-UTR
11	rs1131499	A/G	121632158	3′-UTR
12	rs147839956	G/C	121632779	3′-UTR
13	rs183106460	G/A	121633119	3′-UTR
14	rs77931594	C/A	121633472	3′-UTR

Note:

‡ Minor allele/major allele.

Abbreviations: dbSNP, single nucleotide polymorphism database; SAD, sporadic Alzheimer’s disease; SNPs, single nucleotide polymorphisms; UTR, untranslated region.

Table 3 Association study of SORL1 gene SNPs under different models

SNP (D/d)	Subjects	HWE	Allele (n, %)		Genotype (n, %)			D vs d		DD vs dd		DD + Dd vs dd		DD vs Dd + dd
			D	d	DD	Dd	dd	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
rs57785427 (A/C)	SAD	0.521	15 (7.1)	187 (88.2)	1 (0.9)	13 (12.3)	87 (82.1)	1.17 (0.60–2.29)	0.66	1.09 (0.53–2.23)	0.81	1.09 (0.53–2.23)	0.81	0.19 (0.01–4.62)	0.31
	Controls	0.358	23 (6.4)	335 (93.6)	0 (0.0)	23 (12.8)	156 (87.2)
rs4935774 (C/T)	SAD	0.540	34 (16.0)	168 (79.2)	2 (1.9)	30 (28.3)	69 (65.1)	0.90 (0.57–1.41)	0.63	1.12 (0.18–6.88)	1.00	1.22 (0.73–2.03)	0.44	0.84 (0.14–5.14)	1.00
	Controls	0.125	66 (18.4)	292 (81.6)	3 (1.7)	60 (33.5)	116 (64.8)
rs140041029 (T/G)	SAD	0.799	5 (1.2)	197 (92.9)	0 (0.0)	5 (4.7)	96 (90.6)	0.73 (0.25–2.11)	0.56	0.99 (0.98–1.01)	1.00	1.26 (0.42–3.73)	0.68	0.99 (0.98–1.01)	1.00
	Controls	0.065	12 (3.4)	346 (96.6)	1 (0.6)	10 (5.6)	168 (93.9)
rs189323512 (C/T)	SAD	0.960	1 (0.5)	201 (94.8)	0 (0.0)	1 (0.9)	100 (94.3)	1.78 (0.11–28.5)	0.68	–	–	0.56 (0.04–9.08)	1.00	–	–
	Controls	0.970	1 (0.3)	357 (99.7)	0 (0.0)	1 (0.6)	178 (99.4)
rs10892762 (G/A)	SAD	0.063	89 (42.0)	113 (53.3)	15 (14.2)	59 (55.7)	27 (25.5)	1.35 (0.95–1.92)	0.09	1.69 (0.77–3.72)	0.19	1.76 (1.03–2.99)	0.04	0.85 (0.42–1.71)	0.64
	Controls	0.668	132 (36.9)	226 (63.1)	23 (12.8)	86 (48.0)	70 (39.1)
rs117097913 (G/A)	SAD	0.617	16 (7.5)	186 (87.7)	1 (0.9)	14 (13.2)	86 (81.1)	1.31 (0.67–2.56)	0.42	0.54 (0.03–8.81)	1.00	1.31 (0.64–2.68)	0.45	0.56 (0.03–9.08)	1.00
	Controls	0.675	22 (6.1)	336 (93.9)	1 (0.6)	20 (11.2)	158 (88.3)
rs10790449 (T/C)	SAD	0.063	89 (42.0)	113 (53.3)	15 (14.2)	59 (55.7)	27 (25.5)	1.36 (0.96–1.94)	0.08	1.72 (0.78–3.77)	0.18	1.81 (1.06–3.07)	0.03	0.85 (0.42–1.71)	0.64
	Controls	0.755	131 (36.6)	227 (63.4)	23 (12.8)	85 (47.5)	71 (39.7)
rs1133174 (G/A)	SAD	0.874	58 (27.4)	144 (67.9)	8 (7.5)	42 (39.6)	51 (48.1)	1.92 (1.28–2.90)	0.002#	3.22 (1.06–9.74)	0.03	2.15 (1.30–3.56)	0.003#	0.40 (0.14–1.20)	0.09
	Controls	0.742	62 (17.3)	296 (82.7)	6 (3.4)	50 (27.9)	123 (68.7)
rs1131497 (C/G)	SAD	0.063	89 (42.0)	113 (53.3)	15 (14.2)	59 (55.7)	27 (25.5)	1.36 (0.96–1.94)	0.08	1.72 (0.78–3.77)	0.18	1.81 (1.06–3.07)	0.03	0.85 (0.42–1.71)	0.64
	Controls	0.755	131 (36.6)	227 (63.4)	23 (12.8)	85 (47.5)	71 (39.7)
rs3087925 (A/G)	SAD	0.063	89 (42.0)	113 (53.3)	15 (14.2)	59 (55.7)	27 (25.5)	1.36 (0.96–1.94)	0.08	1.72 (0.78–3.77)	0.18	1.81 (1.06–3.07)	0.03	0.85 (0.42–1.71)	0.64
	Controls	0.755	131 (36.6)	227 (63.4)	23 (12.8)	85 (47.5)	71 (39.7)
rs1131499 (A/G)	SAD	0.063	89 (42.0)	113 (53.3)	15 (14.2)	59 (55.7)	27 (25.5)	1.36 (0.96–1.94)	0.08	1.72 (0.78–3.77)	0.18	1.81 (1.06–3.07)	0.03	0.85 (0.42–1.71)	0.64
	Controls	0.755	131 (36.6)	227 (63.4)	23 (12.8)	85 (47.5)	71 (39.7)
rs147839956 (G/C)	SAD	0.879	3 (1.4)	199 (93.9)	0 (0.0)	3 (2.8)	98 (92.5)	1.78 (0.36–8.92)	0.77	–	–	0.56 (0.11–2.81)	0.77	–	–
	Controls	0.910	3 (0.8)	355 (99.2)	0 (0.0)	3 (1.7)	176 (98.3)
rs183106460 (G/A)	SAD	0.920	2 (0.9)	200 (94.3)	0 (0.0)	2 (1.9)	99 (93.4)	0.39 (0.08–1.81)	0.35	–	–	2.62 (0.56–12.4)	0.35	–	–
	Controls	0.730	9 (2.5)	349 (97.5)	0 (0.0)	9 (5.0)	170 (95.0)
rs77931594 (C/A)	SAD	0.409	42 (19.8)	160 (75.5)	3 (2.8)	36 (34.0)	62 (58.5)	1.06 (0.69–1.63)	0.79	0.74 (0.16–3.40)	1.00	1.05 (0.64–1.74)	0.84	0.75 (0.16–3.40)	1.00
	Controls	0.153	71 (19.8)	287 (80.2)	4 (2.2)	63 (35.2)	112 (62.6)

Notes: “D/d” indicates minor allele/major allele; “D vs d” indicates allelic model; “DD vs dd” indicates homozygote model; “DD + Dd vs dd” indicates dominant model; “DD vs Dd + dd” indicates recessive model.

# Adjusted P-value is 0.028 (allelic model) and 0.042 (dominant model) after Bonferroni correction, respectively.

Abbreviations: CI, confidence interval; HWE, Hardy–Weinberg equilibrium; OR, odds ratio; SAD, sporadic Alzheimer’s disease; SNPs, single nucleotide polymorphisms.

Our results suggest that there is a significant association of the “G” allele of SNP rs1133174 in the 3′-UTR of the SORL1 gene and SAD risk (odds ratio =1.92, 95% confidence interval =1.28–2.90, adjusted P=0.028). Moreover, the “G” allele carriers of rs1133174 (GA + GG) have a 2.15-fold increased risk of SAD compared to noncarriers (AA; adjusted P=0.042) via a dominant model (Table 3). In addition, a logistic regression analysis revealed consistent results (Table 4). However, no significant positive associations were observed in the other 13 SNPs within the SORL1 gene. In addition, we constructed haplotype blocks using our own genotyping data for patients with SAD and controls (Table 3). Two complete linkage disequilibrium regions as well as the D′ and r² values are provided (Figure 1). However, we failed to detect any positive haplotype signals in the present study (Table 5).

Figure 1 Linkage disequilibrium (LD) analyses for the SORL1 gene generated from genotype data in 106 patients with SAD and 179 healthy controls.

Note: r² (A) and D′ (B) LD values are shown separately.
Abbreviation: SAD, sporadic Alzheimer’s disease.

Table 4 Risk estimate using a logistic regression model for SORL1 SNP rs1133174

Group	Model	OR (95% CI)a	P-value
SAD	G vs A	1.906 (1.263–2.876)	0.002
	(GG + GA) vs AA	2.129 (1.287–3.521)	0.003

Note:

a OR value is adjusted by sex and age.

Abbreviations: CI, confidence interval; OR, odds ratio; SAD, sporadic Alzheimer’s disease; SNP, single nucleotide polymorphism.

Table 5 Estimated haplotype frequencies in patients with SAD and control subjects

Gene	Block	Haplotype	Case (freq)	Control (freq)	χ^2	P-value	OR (95% CI)
SORL1	rs10790449-rs1133174-rs1131497	ACA	89 (0.44)	131 (0.37)	3.019	0.082	1.37 (0.96–1.94)
		GCG	113 (0.56)	227 (0.63)	3.019	0.082	0.73 (0.52–1.04)
	rs1131499-rs147839956	AA	113 (0.56)	226 (0.63)	2.793	0.095	0.74 (0.52–1.05)
		GA	73 (0.36)	110 (0.31)	1.721	0.189	1.28 (0.89–1.84)
		GG	16 (0.08)	22 (0.06)	0.642	0.423	1.31 (0.67–2.56)

Note: Haplotypes were omitted from analysis if the estimated haplotype probabilities were less than 3%.

Abbreviations: CI, confidence interval; freq, frequency; OR, odds ratio; SAD, sporadic Alzheimer’s disease.

Discussion

Previous findings show that genetics variants within the SORL1 gene are significantly associated with AD susceptibility in the Han Chinese population.^13,20–24 To identify new genetic variants within the SORL1 gene associated with SAD susceptibility in the Han Chinese population, we performed this two-step study. To our knowledge, this is the first study to associate the “G” allele within the SORL1 SNP rs1133174 with an increased risk of SAD in the Han Chinese population. The SNP rs1133174 is located in the 3′-UTR of the SORL1 gene. Usually, as a regulatory SNP (rSNP), rs1133174, would not influence the amino acid sequences or function of the protein directly. The results of the functional prediction from rSNPBase database suggest that the SORL1 SNP rs1133174 may be involved in transcriptional regulation and may affect the expression quantitative trait loci of multiple genes (data not shown). Importantly, a previous study indicated that the SNP rs1133174 was significantly associated with hippocampal atrophy in older persons.²⁵ The converging evidence suggests that the further functional investigation is warranted.

One purpose of the present study is to identify new uncommon variants within the SORL1 gene associated with the risk of AD. Several SNPs with lower frequencies (such as rs189323512, rs147839956, and rs183106460) were found during the sequencing stage, but no significant positive associations were observed. However, the relatively small sample size is a major limitation in the present study and may affect the interpretation of the results, particularly for rare variants (lower power). In addition, we reported that SORL1 SNP rs985421 might play a contrasting role in the Han Chinese compared to Japanese subjects,¹³ which suggests that populations from different geographic regions may exhibit different genetic markers for AD development. Although participants who were not born in Jiangsu or whose family was not born in Jiangsu were excluded, we could not completely eliminate the effect of different ethnic origins on the results, which is also a limitation of this study. As previously discussed, the SORL1 gene is a valuable susceptibility gene for AD, whereas the actual functional variants associated with AD risk within the SORL1 gene remain unknown. Although the current results are preliminary, they provide new insights into the association of SORL1 with the risk of AD. Notably, AD is a multifactorial disease affected by both inherited and environmental factors, and APOE ε4 is the most prevalent genetic risk factor for SAD.²⁶ Therefore, follow-up studies with large-scale samples and stratified analyses of APOE ε4-status are necessary in the future.

In summary, this case-control study of the Han Chinese population suggests that an rSNP within the SORL1 gene, rs1133174, might affect SAD risk. However, the present findings and the association of rs1133174 with previously published risk loci must be further validated and investigated.

Acknowledgments

We thank all participants in this study. This work was supported by a grant from Wuxi Municipal Health Bureau Foundation (Q201208), Science and Technology Development Foundation of Nanjing Medical University (2013NJMU203), and Excellent Young Talents Project of Wuxi Municipal Health Bureau.

Disclosure

The authors report no conflicts of interest in this work.